David Good

1.6k total citations · 1 hit paper
35 papers, 1.2k citations indexed

About

David Good is a scholar working on Pathology and Forensic Medicine, Hematology and Molecular Biology. According to data from OpenAlex, David Good has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 10 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in David Good's work include Lymphoma Diagnosis and Treatment (13 papers), Acute Myeloid Leukemia Research (5 papers) and Drug Solubulity and Delivery Systems (5 papers). David Good is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Acute Myeloid Leukemia Research (5 papers) and Drug Solubulity and Delivery Systems (5 papers). David Good collaborates with scholars based in Canada, United States and Germany. David Good's co-authors include Naír Rodríguez‐Hornedo, Adivaraha Jayasankar, Randy D. Gascoyne, Michael J. Rauh, John R. Crison, Fazlur Rahman, John M. Bennett, Daniel H. Ryan, Richard Burack and Nikolay Dimov and has published in prestigious journals such as Blood, Pharmaceutical Research and Journal of Pharmaceutical Sciences.

In The Last Decade

David Good

32 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Solubility Advantage of Pharmaceutical Cocrystals

2009 731 citations David Good et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Good Canada	14	737	673	237	182	154	35	1.2k
Mikio Yagi Japan	20	301 0.4×	421 0.6×	233 1.0×	23 0.1×	219 1.4×	115	1.2k
Jan Čejka Czechia	19	251 0.3×	172 0.3×	350 1.5×	77 0.4×	261 1.7×	120	1.3k
Xiaoming Luo China	11	136 0.2×	348 0.5×	198 0.8×	31 0.2×	317 2.1×	26	956
Sanjay R. Chemburkar United States	13	384 0.5×	227 0.3×	300 1.3×	118 0.6×	176 1.1×	17	845
Kunio Okamoto Japan	22	200 0.3×	322 0.5×	959 4.0×	89 0.5×	350 2.3×	158	1.8k
Jordi Teixidó Spain	22	440 0.6×	127 0.2×	662 2.8×	22 0.1×	507 3.3×	111	1.6k
Jo Klaveness Norway	23	631 0.9×	33 0.0×	352 1.5×	71 0.4×	326 2.1×	92	1.6k
Ryusuke Takano Japan	11	512 0.7×	307 0.5×	102 0.4×	512 2.8×	118 0.8×	13	951
Thierry Terme France	19	156 0.2×	118 0.2×	1.0k 4.4×	76 0.4×	223 1.4×	108	1.4k
Walter Wolf United States	24	284 0.4×	47 0.1×	344 1.5×	60 0.3×	297 1.9×	106	1.7k

Countries citing papers authored by David Good

Since Specialization

Citations

This map shows the geographic impact of David Good's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Good with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Good more than expected).

Fields of papers citing papers by David Good

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Good. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Good. The network helps show where David Good may publish in the future.

Co-authorship network of co-authors of David Good

This figure shows the co-authorship network connecting the top 25 collaborators of David Good. A scholar is included among the top collaborators of David Good based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Good. David Good is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morris, Nicola, Christine L. D’Arsigny, Paula James, et al.. (2025). Adjust-Unlikely pulmonary embolism testing using telephone recruitment: a pilot study to assess the feasibility of evaluating its safety and efficiency. Emergency Medicine Journal. 42(8). 496–502.

Aburub, Aktham, Yuan Chen, Ping Gao, et al.. (2022). An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow. The AAPS Journal. 24(3). 49–49. 8 indexed citations

Snetsinger, Brooke, Xiao Zhang, Guillaume Richard‐Carpentier, et al.. (2021). Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay. Journal of Molecular Diagnostics. 23(10). 1292–1305. 7 indexed citations

Gesenberg, Christoph, Neil Mathias, Yan Xu, et al.. (2019). Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy. Pharmaceutical Research. 36(12). 164–164. 15 indexed citations

Vaidhyanathan, Shruthi, Xiaoning Wang, John R. Crison, et al.. (2018). Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling. Journal of Pharmaceutical Sciences. 108(1). 741–749. 36 indexed citations

Cull, Alyssa, Brooke Snetsinger, David Good, et al.. (2017). Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research. 65. 5–13. 15 indexed citations

Chen, Bingshu E., Adnan Mansoor, David P. LeBrun, et al.. (2017). A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. Haematologica. 103(2). 288–296. 13 indexed citations

Nair, Raj, Lakshman P. Samaranayake, Li Zhang, et al.. (2016). The yield and quality of cellular and bacterial DNA extracts from human oral rinse samples are variably affected by the cell lysis methodology. Journal of Microbiological Methods. 122. 64–72. 17 indexed citations

Tyryshkin, Kathrin, David Good, Lois E. Shepherd, et al.. (2016). Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy. Blood. 128(22). 3037–3037. 3 indexed citations

10.

Desai, D., et al.. (2015). Mathematical Model-Based Accelerated Development of Extended-release Metformin Hydrochloride Tablet Formulation. AAPS PharmSciTech. 17(4). 1007–1013. 22 indexed citations

11.

Berinstein, Neil L., Sita Bhella, Nancy Pennell, et al.. (2015). Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Annals of Hematology. 94(5). 813–823. 8 indexed citations

12.

Rauh, Michael J. & David Good. (2014). Bodies of evidence? Lymphoglandular bodies in aspirate smears of bone marrow involved by aggressive large B-cell lymphoma. Blood. 123(24). 3695–3695. 2 indexed citations

13.

Prica, Anca, Matthew C. Cheung, Kim D. Thompson, et al.. (2014). Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature. Journal of Cancer Therapy. 6(1). 1–11. 1 indexed citations

14.

Leduc, Charles, Tara Baetz, David Good, et al.. (2014). Composite Mantle Cell and Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Dermatopathology. 37(3). 232–236. 8 indexed citations

15.

Cull, Alyssa, et al.. (2013). Increased Arginase 1 Expression In Human MDS, CMML and Murine Models Points To Dysregulation Of Common Immunosuppressive Signaling Networks. Blood. 122(21). 1578–1578. 1 indexed citations

16.

Chesney, Alden, David Good, & Marciano D. Reis. (2011). Clinical Utility of Flow Cytometry in the Study of Erythropoiesis and Nonclonal Red Cell Disorders. Methods in cell biology. 103. 311–332. 8 indexed citations

17.

Rauh, Michael J., Fazlur Rahman, David Good, et al.. (2011). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. Leukemia Research. 36(1). 81–86. 66 indexed citations

18.

Good, David & Randy D. Gascoyne. (2009). Atypical Lymphoid Hyperplasia Mimicking Lymphoma. Hematology/Oncology Clinics of North America. 23(4). 729–745. 31 indexed citations

19.

Good, David & Randy D. Gascoyne. (2008). Classification of Non-Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America. 22(5). 781–805. 15 indexed citations

20.

Good, David, Stephen A. Morse, Héctor O. Ventura, & Efrain Reisin. (2008). Obesity, Hypertension, and the Heart. PubMed. 3(3). 168–172. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact